Evidence map›Paper›PMID 34029681›Full record

Observational studyAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2021

Risk of Potentially Inappropriate Medications in Adults With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.

Rasheeda K Hall, Jacob B Blumenthal, Rebecca M Doerfler, Jing Chen, Clarissa J Diamantidis, Bernard G Jaar, John W Kusek, Krishna Kallem, Mary B Leonard, Sankar D Navaneethan and 7 more

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Safety and Effectiveness of Nirmatrelvir-Ritonavir in Patients With Advanced Kidney Dysfunction and COVID-19.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 1 country.

Rasheeda K HallRenal Section, Department of Medicine, School of Medicine, Duke University, and Durham Veterans Affairs Healthcare System, Durham, North Carolina. Electronic address: rasheeda.stephens@dm.duke.edu.
Jacob B BlumenthalDivision of Gerontology & Geriatric Medicine School of Medicine, University of Maryland, Baltimore, Maryland; Baltimore Geriatrics Research, Department of Medicine, Education and Clinical Center (GRECC), Baltimore Veterans Affairs and Medical Center, Baltimore, Maryland.
Rebecca M DoerflerDepartment of Medicine, School of Medicine, University of Maryland, Baltimore, Maryland.
Jing ChenDepartment of Medicine, School of Medicine, Tulane University, New Orleans, Louisiana.
Clarissa J DiamantidisRenal Section, Department of Medicine, School of Medicine, Duke University, and Durham Veterans Affairs Healthcare System, Durham, North Carolina.
Bernard G JaarDepartment of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
John W KusekCenter for Clinical Epidemiology and Biostatistics, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Krishna KallemDepartment of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Mary B LeonardDepartment of Pediatrics, Stanford University School of Medicine, Palo Alto, California.
Sankar D NavaneethanSection of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas.
Daohang ShaCenter for Clinical Epidemiology and Biostatistics, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
James H SondheimerDepartment of Medicine, School of Medicine, Wayne State University, Detroit, Michigan.
Lee-Ann WagnerDepartment of Medicine, School of Medicine, University of Maryland, Baltimore, Maryland.
Wei YangCenter for Clinical Epidemiology and Biostatistics, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Min ZhanDepartment of Epidemiology and Public Health, School of Medicine, University of Maryland, Baltimore, Maryland.
Jeffrey C FinkDepartment of Medicine, School of Medicine, University of Maryland, Baltimore, Maryland.
CRIC Study Investigators
University of Maryland, Baltimore · USUniversity of Pennsylvania · USDuke University · USBaylor College of Medicine · USChildren's Hospital of Philadelphia · USJohns Hopkins University · USStanford University · USTulane University · USWayne State University · US

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Scientific and Data Coordinating Center(SDCC) for the P*U01DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI FELDMAN, HAROLD I · 2001 to 2017
$50.1M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
Institutional Clinical and Translational Science AwardUL1TR000003 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2012 to 2015
$38.9M
Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5M
Continuation of the Coordinating Center for the Chronic Renal Insufficiency Cohort (CRIC) StudyU24DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Amanda Hyre Anderson, Laura M Dember · 2018 to 2026
$21.5M
Zonulin Antibodies in Intestinal Permeabilitiy in IDDMM01RR016500 · NCRR · UNIVERSITY OF MARYLAND BALTIMORE · PI ONUKWUGHA, EBERECHUKWU · 2002 to 2009
$20.2M
Study of the Care and Outcomes of REnal InsufficiencyU01DK060902 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI GO, ALAN S · 2001 to 2025
$19.5M
Limited Competition for the Continuation of the Chronic Renal Insufficiency CohorU01DK061021 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI RAHMAN, MAHBOOB · 2001 to 2025
$17.3M
Prospective Renal Insufficiency Cohort Evaluation:PRICEU01DK060984 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI COHEN, DEBBIE L · 2001 to 2025
$17.0M
Prospective Cohort Study of Chronic Renal InsufficiencyU01DK061028 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RAO, PANDURANGA S · 2001 to 2025
$16.9M
NCATS NIH HHS UL1 TR000003NCATS NIH HHS UL1 TR000424NCATS NIH HHS UL1 TR000433NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1 TR002548NCRR NIH HHS M01 RR016500NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1 RR029879NIA NIH HHS K76 AG059930NIDDK NIH HHS L30 DK115059NIDDK NIH HHS R01 DK090008NIDDK NIH HHS R01 DK139225NIDDK NIH HHS R21 DK130018NIDDK NIH HHS U01 DK060902NIDDK NIH HHS U01 DK060963NIDDK NIH HHS U01 DK060980NIDDK NIH HHS U01 DK060984NIDDK NIH HHS U01 DK060990NIDDK NIH HHS U01 DK061021NIDDK NIH HHS U01 DK061022NIDDK NIH HHS U01 DK061028NIDDK NIH HHS U24 DK060990NIGMS NIH HHS P30 GM103337
6 · The paper itself

Abstract

RATIONALE &

objectiveAdults with chronic kidney disease (CKD) may be at increased risk of adverse effects from use of potentially inappropriate medications (PIMs). Our objective was to assess whether PIM exposure has an independent association with CKD progression, hospitalizations, mortality, or falls. STUDY

designRetrospective observational study. SETTING &

participantsChronic Renal Insufficiency Cohort (CRIC) study; 3,929 adults with CKD enrolled 2003-2008 and followed prospectively until December 2011. EXPOSURE: PIM exposure was defined as prescriptions for any medications to be avoided in older adults as defined by the 2015 American Geriatrics Society Beers Criteria. OUTCOME: Hospitalization count, death, a composite kidney disease end point of CKD progression or initiation of kidney replacement therapy (KRT), KRT, and fall events assessed 1 year after PIM exposure. ANALYTICAL APPROACH: Logistic regression and Poisson regression to estimate the associations of PIM exposure with each outcome.

resultsThe most commonly prescribed PIMs were proton pump inhibitors and α-blockers. In unadjusted models, any PIM exposure (compared to none) was associated with hospitalizations, death, and fall events. After adjustment, exposure to 1, 2, or≥3 PIMs had a graded association with a higher hospitalization rate (rate ratios of 1.09 [95% CI, 1.01-1.17], 1.18 [95% CI, 1.07-1.30], and 1.35 [95% CI, 1.19-1.53], respectively) and higher odds of mortality (odds ratios of 1.19 [95% CI, 0.91-1.54], 1.62 [95% CI, 1.21-2.17], and 1.65 [95% CI, 1.14-2.41], respectively). In a cohort subset reporting falls (n=1,109), prescriptions for≥3 PIMs were associated with an increased risk of falls (adjusted OR, 2.85 [95% CI, 1.54-5.26]). PIMs were not associated with CKD progression or KRT. Age did not modify the association between PIM count and outcomes. LIMITATIONS: Measurement bias; confounding by indication.

conclusionsAdults of any age with CKD who are prescribed PIMs have an increased risk of hospitalization, mortality, and falls with the greatest risk occurring after more than 1 PIM prescription.

Indexed as

Potentially Inappropriate Medication ListRenal Insufficiency, ChronicAgedCohort StudiesHospitalizationHumansInappropriate PrescribingRetrospective StudiesAdverse drug eventadverse outcomeschronic kidney disease (CKD)CKD progressiondrug safetyfallshospitalizationskidney replacement therapy (KRT)mortalitypotentially inappropriate medications (PIMs)prescribing practicesproton pump inhibitors (PPIs)α-blockers

Identifiers

PMID34029681
PMCPMC8608689
OpenAlexW3164419518

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.